| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.BONR.2018.06.002 |
| P953 | full work available at URL | https://linkinghub.elsevier.com/retrieve/pii/S2352187218300354 |
| P932 | PMC publication ID | 6303233 |
| P698 | PubMed publication ID | 30591928 |
| P2093 | author name string | Donald L Trump | |
| P2860 | cites work | First-line crizotinib versus chemotherapy in ALK-positive lung cancer | Q27853101 |
| 1,25-Dihydroxyvitamin D3: in vivo and in vitro effects on human preleukemic and leukemic cells | Q28336543 | ||
| A Phase I trial of calcitriol (1,25-dihydroxycholecalciferol) in patients with advanced malignancy | Q28368222 | ||
| A phase I study of the vitamin D analogue EB 1089 in patients with advanced breast and colorectal cancer | Q28368253 | ||
| Selective inhibition of cyclooxygenase-2 (COX-2) by 1alpha,25-dihydroxy-16-ene-23-yne-vitamin D3, a less calcemic vitamin D analog | Q28575435 | ||
| Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer | Q29616123 | ||
| Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer | Q29616218 | ||
| Dose-response of serum 25-hydroxyvitamin D in association with risk of colorectal cancer: A meta-analysis | Q30239966 | ||
| Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma | Q34115732 | ||
| CYP24A1 inhibition enhances the antitumor activity of calcitriol | Q34132307 | ||
| Association between vitamin D and risk of colorectal cancer: a systematic review of prospective studies | Q34211683 | ||
| Ecological studies of the UVB-vitamin D-cancer hypothesis. | Q34244046 | ||
| Combination of oral vitamin D3 with photodynamic therapy enhances tumor cell death in a murine model of cutaneous squamous cell carcinoma | Q34293524 | ||
| Progesterone enhances calcitriol antitumor activity by upregulating vitamin D receptor expression and promoting apoptosis in endometrial cancer cells | Q34345209 | ||
| Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer | Q44265664 | ||
| High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma | Q44323784 | ||
| Combination treatment with 1alpha,25-dihydroxyvitamin D3 and 9-cis-retinoic acid directly inhibits human telomerase reverse transcriptase transcription in prostate cancer cells. | Q44562290 | ||
| Pharmacokinetics of 1alpha,25-dihydroxyvitamin D3 in normal mice after systemic exposure to effective and safe antitumor doses | Q44805762 | ||
| High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma | Q44866794 | ||
| Tumor-associated stromal cells expressing E-prostanoid 2 or 3 receptors in prostate cancer: correlation with tumor aggressiveness and outcome by angiogenesis and lymphangiogenesis | Q45089573 | ||
| Synthesis and CYP24 inhibitory activity of 2-substituted-3,4-dihydro-2H-naphthalen-1-one (tetralone) derivatives | Q45105767 | ||
| High-dose calcitriol and carboplatin in metastatic androgen-independent prostate cancer | Q45185913 | ||
| Randomized study of high-dose pulse calcitriol or placebo prior to radical prostatectomy | Q45187114 | ||
| Circulating 25-hydroxyvitamin D and lung cancer risk and survival: A dose-response meta-analysis of prospective cohort studies. | Q45910508 | ||
| Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells | Q46051825 | ||
| Vitamin D3 analogs and their 24-oxo metabolites equally inhibit clonal proliferation of a variety of cancer cells but have differing molecular effects | Q46218649 | ||
| A phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancer | Q46377734 | ||
| Pharmacokinetics of liquid calcitriol formulation in advanced solid tumor patients: comparison with caplet formulation | Q46511446 | ||
| Pharmacokinetics and tolerability of a single dose of DN-101, a new formulation of calcitriol, in patients with cancer | Q46797226 | ||
| Phase I/II study of 19-nor-1alpha-25-dihydroxyvitamin D2 (paricalcitol) in advanced, androgen-insensitive prostate cancer | Q46856587 | ||
| Inhibition of Vitamin D3 metabolism enhances VDR signalling in androgen-independent prostate cancer cells. | Q46948865 | ||
| Coexpression of NOS2 and COX2 accelerates tumor growth and reduces survival in estrogen receptor-negative breast cancer | Q47105736 | ||
| Meta-analysis of the correlation between vitamin D and lung cancer risk and outcomes | Q47130707 | ||
| NO and COX2: Dual targeting for aggressive cancers. | Q48122606 | ||
| Vitamin D supplementation decreases serum 27-hydroxycholesterol in a pilot breast cancer trial. | Q48342697 | ||
| Correlation of Inflammatory Markers, Survival, and COX2 Expression in Oral Cancer and Implications for Prognosis | Q49850767 | ||
| Inhibition of lung carcinogenesis by 1alpha,25-dihydroxyvitamin D3 and 9-cis retinoic acid in the A/J mouse model: evidence of retinoid mitigation of vitamin D toxicity. | Q51481770 | ||
| Comparative effects of 1,25(OH)2D3 and EB1089 on cell cycle kinetics and apoptosis in MCF-7 breast cancer cells. | Q52525004 | ||
| Indometacin inhibits the proliferation and activation of human pancreatic stellate cells through the downregulation of COX-2. | Q52642934 | ||
| The VITamin D and OmegA-3 TriaL-Depression Endpoint Prevention (VITAL-DEP): Rationale and design of a large-scale ancillary study evaluating vitamin D and marine omega-3 fatty acid supplements for prevention of late-life depression. | Q52662001 | ||
| Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. | Q52692152 | ||
| Presence of 1,25-dihydroxyvitamin D3 receptors in established human cancer cell lines in culture | Q52828892 | ||
| 1,25(OH)2D3 attenuates TGF-β1/β2-induced increased migration and invasion via inhibiting epithelial-mesenchymal transition in colon cancer cells. | Q52905369 | ||
| Vitamin D Supplementation Decreases TGF-β1 Bioavailability in PCOS: A Randomized Placebo-Controlled Trial. | Q52908360 | ||
| Circulating 25-hydroxyvitamin D serum concentration and total cancer incidence and mortality: a systematic review and meta-analysis | Q34371127 | ||
| The role of vitamin D in reducing cancer risk and progression | Q34413846 | ||
| Mechanisms implicated in the growth regulatory effects of vitamin D in breast cancer | Q34577228 | ||
| 24- and 26-homo-1,25-dihydroxyvitamin D3: preferential activity in inducing differentiation of human leukemia cells HL-60 in vitro | Q34616473 | ||
| Vitamin D receptor: a potential target for intervention | Q34856813 | ||
| 1,25-Dihydroxyvitamin D3 and its analog TX527 promote a stable regulatory T cell phenotype in T cells from type 1 diabetes patients | Q35298711 | ||
| Differential expression and regulation of vitamin D hydroxylases and inflammatory genes in prostate stroma and epithelium by 1,25-dihydroxyvitamin D in men with prostate cancer and an in vitro model | Q35322827 | ||
| Differentiation of mouse myeloid leukemia cells induced by 1 alpha,25-dihydroxyvitamin D3 | Q35462970 | ||
| Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA Studies | Q35501693 | ||
| A vitamin D analogue (EB1089) inhibits parathyroid hormone-related peptide production and prevents the development of malignancy-associated hypercalcemia in vivo | Q35610145 | ||
| Inecalcitol, an analog of 1α,25(OH)(2) D(3) , induces growth arrest of androgen-dependent prostate cancer cells | Q35782892 | ||
| Anti-tumor activity of calcitriol: pre-clinical and clinical studies | Q35822339 | ||
| A local effect of CYP24 inhibition on lung tumor xenograft exposure to 1,25-dihydroxyvitamin D(3) is revealed using a novel LC-MS/MS assay | Q35830723 | ||
| Plasma vitamin D levels, menopause, and risk of breast cancer: dose-response meta-analysis of prospective studies | Q36009017 | ||
| Interaction of nuclear receptor ligands with the Vitamin D signaling pathway in prostate cancer | Q36017052 | ||
| 25-Hydroxycholecalciferol receptors in human breast cancer | Q36043051 | ||
| Synthesis and biological activities of vitamin D-like inhibitors of CYP24 hydroxylase | Q36515135 | ||
| The antitumor efficacy of calcitriol: preclinical studies. | Q36555798 | ||
| A phase II trial of the vitamin D analogue Seocalcitol (EB1089) in patients with inoperable pancreatic cancer | Q36644189 | ||
| A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma | Q36670965 | ||
| Trastuzumab for the treatment of salivary duct carcinoma | Q36714388 | ||
| Inecalcitol, an analog of 1,25D3, displays enhanced antitumor activity through the induction of apoptosis in a squamous cell carcinoma model system | Q36724263 | ||
| Toxicity Attribution in Phase I Trials: Evaluating the Effect of Dose on the Frequency of Related and Unrelated Toxicities | Q36761020 | ||
| Minireview: Androgen metabolism in castration-resistant prostate cancer | Q36789277 | ||
| A phase I/II pharmacokinetic and pharmacogenomic study of calcitriol in combination with cisplatin and docetaxel in advanced non-small-cell lung cancer | Q36799473 | ||
| SULT2B1b sulfotransferase: induction by vitamin D receptor and reduced expression in prostate cancer | Q36850145 | ||
| Phase II open label, multi-center clinical trial of modulation of intermediate endpoint biomarkers by 1α-hydroxyvitamin D2 in patients with clinically localized prostate cancer and high grade pin. | Q37127088 | ||
| 1α,25(OH)₂D₃ Suppresses the Migration of Ovarian Cancer SKOV-3 Cells through the Inhibition of Epithelial-Mesenchymal Transition | Q37210064 | ||
| A phase I and pharmacokinetics study of intravenous calcitriol in combination with oral dexamethasone and gefitinib in patients with advanced solid tumors | Q37352021 | ||
| Role of vitamin D receptor in the antiproliferative effects of calcitriol in tumor-derived endothelial cells and tumor angiogenesis in vivo | Q37363014 | ||
| 1 alpha,25-Dihydroxyvitamin D3 and 1 alpha-hydroxyvitamin D3 prolong survival time of mice inoculated with myeloid leukemia cells | Q37600754 | ||
| Molecular pathways mediating the anti-inflammatory effects of calcitriol: implications for prostate cancer chemoprevention and treatment | Q37635592 | ||
| Heterogeneity in the definition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents: a review of the literature | Q37863861 | ||
| 1α,25-Dihydroxyvitamin D3 and its analogs as modulators of human dendritic cells: a comparison dose-titration study | Q38055537 | ||
| Vitamin D deficiency impairs rituximab-mediated cellular cytotoxicity and outcome of patients with diffuse large B-cell lymphoma treated with but not without rituximab. | Q53085386 | ||
| Inhibition of cancer growth and induction of apoptosis by BGP-13 and BGP-15, new calcipotriene-derived vitamin D3 analogs, in-vitro and in-vivo studies. | Q53165076 | ||
| Expression of cyclooxygenase-2 in prostate carcinoma. | Q53407074 | ||
| A phase I pharmacokinetic and pharmacodynamic study of intravenous calcitriol in combination with oral gefitinib in patients with advanced solid tumors. | Q53577477 | ||
| Phase II trial of high-dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) and dexamethasone in androgen-independent prostate cancer. | Q53600128 | ||
| COX2/PTGS2 Expression Is Predictive of Response to Neoadjuvant Celecoxib in HER2-negative Breast Cancer Patients. | Q54096339 | ||
| Induction of macrophage differentiation of human normal and leukemic myeloid stem cells by 1,25-dihydroxyvitamin D3 and its fluorinated analogues. | Q54361379 | ||
| Antitumor effect of 1 alpha-hydroxyvitamin D3. | Q54660359 | ||
| Serum 25-Hydroxyvitamin D and Cancer Risk in Older Adults: Results from a Large German Prospective Cohort Study | Q57191881 | ||
| Prospective Population-Based Study of the Association between Serum 25-Hydroxyvitamin-D Levels and the Incidence of Specific Types of Cancer | Q57401860 | ||
| Randomized Clinical Trial of Vitamin D3 Doses on Prostatic Vitamin D Metabolite Levels and Ki67 Labeling in Prostate Cancer Patients | Q63966311 | ||
| Suppression by vitamins D2 and D3 of hamster cheek pouch carcinoma induced with 9,10-dimethyl-1,2-benzanthracene with a discussion of the role of intracellular calcium in the development of tumors | Q68671895 | ||
| Synthetic studies of vitamin D3 analogues. VIII. Synthesis of 22-oxavitamin D3 analogues | Q69782785 | ||
| Abolition of L1210 clonogeneticy and G1 arrest by retinoic acid and 1,25-dihydroxyvitamin D3 | Q69802896 | ||
| Action of 1,25-(OH)2D3 in nude mice bearing transplantable human myelogenous leukemic cell lines | Q69844875 | ||
| Biochemical significance of enhanced activity of fluorinated 1,25-dihydroxyvitamin D3 in human cultured cell lines | Q70139849 | ||
| Inhibition of human cancer cell growth by 1,25-dihydroxyvitamin D3 metabolites | Q70152723 | ||
| Induction of differentiation of the human histiocytic lymphoma cell line U-937 by 1 alpha,25-dihydroxycholecalciferol | Q70174475 | ||
| Specific uptake of 1,25-dihydroxycholecalciferol by human chronic myeloid leukemia cells | Q70222274 | ||
| Cyclin-dependent kinase inhibitor p27 as a mediator of the G1-S phase block induced by 1,25-dihydroxyvitamin D3 in HL60 cells | Q70840022 | ||
| The synthesis of vitamin D metabolites by human melanoma cells | Q70990656 | ||
| Enhancement of antiproliferative activity of 1alpha,25-dihydroxyvitamin D3 (analogs) by cytochrome P450 enzyme inhibitors is compound- and cell-type specific | Q71114381 | ||
| 1,25-dihydroxyvitamin D3 inhibits proliferation of human promyelocytic leukaemia (HL60) cells and induces monocyte-macrophage differentiation in HL60 and normal human bone marrow cells | Q71229333 | ||
| Effects of 1,25 dihydroxyvitamin D3 and its analogues on induction of apoptosis in breast cancer cells | Q71748819 | ||
| 1,25-dihydroxyvitamin D3 receptors in human epithelial cancer cell lines | Q71858538 | ||
| 1 alpha,25-Dihydroxyvitamin D3 induces differentiation of human myeloid leukemia cells | Q72025020 | ||
| 1,25-dihydroxyvitamin D3 receptors in cancer | Q72421564 | ||
| 1,25-dihydroxyvitamin D3 receptors in cancer | Q72425018 | ||
| Significance of 1, 25-dihydroxyvitamin-D "receptors" in normal and malignant breast tissue | Q72425347 | ||
| 1,25-dihydroxyvitamin D3 and malignant melanoma: the presence of receptors and inhibition of cell growth in culture | Q72878839 | ||
| Presence of 1,25-dihydroxy vitamin D receptor in normal and abnormal breast tissue | Q72884689 | ||
| Normal and malignant breast tissue is a target organ for 1,25-(0H)2 vitamin D3 | Q72886452 | ||
| Frequency of 1,25-dihydroxyvitamin D3 receptor in human breast cancer | Q72914463 | ||
| Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma | Q73223395 | ||
| Genistein and vitamin D synergistically inhibit human prostatic epithelial cell growth | Q78340496 | ||
| Inhibitors of vitamin D hydroxylases: structure-activity relationships | Q78769457 | ||
| Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer | Q79303399 | ||
| Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators | Q79794482 | ||
| Cyclooxygenase-2 expression correlates with local chronic inflammation and tumor neovascularization in human prostate cancer | Q81707914 | ||
| Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer | Q83169185 | ||
| Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer | Q83831101 | ||
| Does vitamin D mediate inhibition of epithelial ovarian cancer by modulating cytokines? | Q86869736 | ||
| The vitamin D analog TX527 ameliorates disease symptoms in a chemically induced model of inflammatory bowel disease | Q87352281 | ||
| Cell cycle arrest and apoptosis induced by 1α,25(OH)2D3 and TX 527 in Kaposi sarcoma is VDR dependent | Q38169478 | ||
| 1alpha,25-dihydroxyvitamin D(3) (calcitriol) and its analogue, 19-nor-1alpha,25(OH)(2)D(2), potentiate the effects of ionising radiation on human prostate cancer cells | Q38305355 | ||
| Progestins inhibit calcitriol-induced CYP24A1 and synergistically inhibit ovarian cancer cell viability: An opportunity for chemoprevention | Q38776186 | ||
| 1α,25-Dihydroxyvitamin D3 Inhibits Esophageal Squamous Cell Carcinoma Progression by Reducing IL6 Signaling | Q38892989 | ||
| Targeting PD-1/PD-L1 in lung cancer: current perspectives | Q38956294 | ||
| Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies | Q39010566 | ||
| Vitamin D receptor agonist EB1089 is a potent regulator of prostatic "intracrine" metabolism | Q39062220 | ||
| 'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations. | Q39136403 | ||
| Vitamin D analogue TX 527 down-regulates the NF-κB pathway and controls the proliferation of endothelial cells transformed by Kaposi sarcoma herpesvirus | Q39155786 | ||
| Androgen deprivation promotes intratumoral synthesis of dihydrotestosterone from androgen metabolites in prostate cancer | Q39176498 | ||
| Vitamin D analogues: Potential use in cancer treatment | Q39191237 | ||
| Regulation of CYP3A4 and CYP3A5 expression and modulation of "intracrine" metabolism of androgens in prostate cells by liganded vitamin D receptor | Q39287367 | ||
| Opposite regulation of vitamin D receptor by ATRA in AML cells susceptible and resistant to vitamin D-induced differentiation | Q39315771 | ||
| CYP24 inhibition preserves 1α,25-dihydroxyvitamin D(3) anti-proliferative signaling in lung cancer cells. | Q39386469 | ||
| 1,25-dihydroxyvitamin-D-receptor in breast cancer cells | Q39579338 | ||
| The D-Health Trial: A randomized trial of vitamin D for prevention of mortality and cancer | Q39845368 | ||
| Antitumor effects of two less-calcemic vitamin D analogs (Paricalcitol and QW-1624F2-2) in squamous cell carcinoma cells | Q40181056 | ||
| A 24-phenylsulfone analog of vitamin D inhibits 1alpha,25-dihydroxyvitamin D(3) degradation in vitamin D metabolism-competent cells | Q40191523 | ||
| Androgen enhances the antiproliferative activity of vitamin D3 by suppressing 24-hydroxylase expression in LNCaP cells | Q40307503 | ||
| Investigation of the mechanisms by which EB1089 abrogates apoptosis induced by 9-cis retinoic acid in pancreatic cancer cells | Q40341429 | ||
| Genistein potentiates the growth inhibitory effects of 1,25-dihydroxyvitamin D3 in DU145 human prostate cancer cells: role of the direct inhibition of CYP24 enzyme activity | Q40410049 | ||
| Induction of apoptosis in breast cancer cells in response to vitamin D and antiestrogens | Q40470534 | ||
| Pre-diagnostic vitamin D concentrations and cancer risks in older individuals: an analysis of cohorts participating in the CHANCES consortium | Q40937152 | ||
| Novel 20-epi-vitamin D3 analog combined with 9-cis-retinoic acid markedly inhibits colony growth of prostate cancer cells | Q40943398 | ||
| Liarozole acts synergistically with 1alpha,25-dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity | Q40958308 | ||
| Modulation of cell growth, differentiation, and production of interleukin-3 by 1 alpha,25-dihydroxyvitamin D3 in the murine myelomonocytic leukemia cell line WEHI-3. | Q41344708 | ||
| 1α,25-Dihydroxycholecalciferol and a human myeloid leukaemia cell line (HL-60) | Q41554261 | ||
| Whole-cell uptake and nuclear localization of 1,25-dihydroxycholecalciferol by breast cancer cells (T47 D) in culture | Q41609946 | ||
| 20-EPI-vitamin D3 analogues: A novel class of potent regulators of cell growth and immune responses | Q41664866 | ||
| Effect of 1 alpha-hydroxyvitamin D3 on metastasis of rat ascites hepatoma K-231. | Q41906213 | ||
| Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3. | Q42275515 | ||
| Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. | Q42514552 | ||
| Action of 1,25(OH)2D3 on the cell cycle genes, cyclin D1, p21 and p27 in MCF-7 cells | Q42538869 | ||
| Differential effects of 1,25-dihydroxyvitamin D3 and tetradecanoylphorbol acetate on cell cycle and apoptosis of MCF-7 cells and a vitamin D3-resistant variant | Q42546942 | ||
| 1 alpha, 25-dihydroxyvitamin D3 (calcitriol) induces apoptosis in stimulated T cells through an IL-2 dependent mechanism | Q42555132 | ||
| Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol) | Q42677963 | ||
| Phase I safety and pharmacodynamic of inecalcitol, a novel VDR agonist with docetaxel in metastatic castration-resistant prostate cancer patients | Q42704868 | ||
| 1 alpha,25-Dihydroxyvitamin D3 markedly enhances chemically-induced transformation in BALB 3T3 cells | Q42820638 | ||
| Specific binding of 1,25-dihydroxycholecalciferol in human medullary thyroid carcinoma | Q42875228 | ||
| Phase 2 trial of weekly intravenous 1,25 dihydroxy cholecalciferol (calcitriol) in combination with dexamethasone for castration-resistant prostate cancer | Q43158086 | ||
| A phase II trial of calcitriol and naproxen in recurrent prostate cancer. | Q43295148 | ||
| Two novel 14-Epi-analogues of 1,25-dihydroxyvitamin D3 inhibit the growth of human breast cancer cells in vitro and in vivo | Q43503491 | ||
| Vitamin D(3)-induced apoptosis of murine squamous cell carcinoma cells. Selective induction of caspase-dependent MEK cleavage and up-regulation of MEKK-1. | Q43594118 | ||
| A Phase I trial of pulse calcitriol in patients with refractory malignancies: pulse dosing permits substantial dose escalation | Q43645557 | ||
| Low plasma 25-hydroxyvitamin D and risk of tobacco-related cancer | Q43776473 | ||
| Phase II study of 1alpha-hydroxyvitamin D(2) in the treatment of advanced androgen-independent prostate cancer | Q43802386 | ||
| Combination of 1alpha,25-dihydroxyvitamin D(3) with dexamethasone enhances cell cycle arrest and apoptosis: role of nuclear receptor cross-talk and Erk/Akt signaling. | Q43829476 | ||
| Preclinical activity of ketoconazole in combination with calcitriol or the vitamin D analogue EB 1089 in prostate cancer cells | Q44156944 | ||
| Pharmacokinetics of high-dose oral calcitriol: results from a phase 1 trial of calcitriol and paclitaxel | Q44259177 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | calcitriol | Q139195 |
| P304 | page(s) | 110-119 | |
| P577 | publication date | 2018-12-01 | |
| P1433 | published in | Bone reports | Q27726039 |
| P1476 | title | Calcitriol and cancer therapy: A missed opportunity | |
| P478 | volume | 9 |
Search more.